Senores Pharma share price rallied as much as 13% on Thursday, July 24, 2025, after the company posted strong financial results for the quarter ended June 30, 2025 (Q1FY26).
At 2:56 PM, the stock was trading 11.13% higher at ₹676 apiece. It opened the day at ₹648, compared to the previous close of ₹608.95.
Since its IPO in December 2024, Senores Pharma has doubled investor wealth in just seven months. The IPO was priced at ₹391 per share, making it one of the best-performing new listings in the pharma sector. Investors who participated in the IPO or bought shares from the secondary market would have done so through a demat account, which is essential for holding stocks in electronic form.
The company delivered strong growth across all key financial metrics:
This performance reflects robust demand, efficient cost management, and strong market presence in key regions.
Senores Pharma earns a major share of its revenue from regulated markets, which made up 65% of total sales in the quarter. This segment generated ₹90 crore, growing 69% YoY and 40% QoQ.
Emerging markets accounted for 21% of revenue, contributing ₹29 crore—a 32% YoY increase, though sales dipped 21% QoQ, possibly due to seasonal changes or inventory adjustments.
The remaining 14% of revenue came from other markets, with ₹18.9 crore in sales, showing a 264% YoY rise, and a small 2% dip sequentially.
During the start of this year, the company launched two ANDA products in regulated markets. It also received approval for four new ANDA drugs in Q1.
The company’s strength lies in its ability to serve both retail and government channels in the US, giving it a competitive edge. Its focus on controlled substance manufacturing and supply also sets it apart in the industry.
Senores Pharma has impressed both investors and analysts with its strong Q1FY26 performance, driven by robust growth in revenue, profit, and EBITDA. The stock’s sharp rise and rapid wealth creation since listing reflect market confidence in the company’s product pipeline, US presence, and strategic focus.
With more product launches and approvals expected in the future, Senores Pharmaceuticals remains a stock to watch in the coming quarters.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 24, 2025, 3:01 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
